MaverikIT Posted - 3 days ago

@DonCorleone77 @IsabellaDC @net0trader @Wigglyick @Cash4freedom @Im_not_Mr_Lebowski @CycleTrade @RonIsWrong 😀 Not all quiet on the eastern front $CWEB $FUTU (ER 5/28 BMO) $BGNE $PDD ....

MaverikIT Posted - 3 days ago

@IsabellaDC @net0trader @DonCorleone77 @Wigglyick @Cash4freedom @Im_not_Mr_Lebowski @CycleTrade @RonIsWrong $CWEB $FUTU $PDD $BGNE ....

Biotech_Beast Posted - 6 days ago

$LPTX The DisTinGuish trial of LPTX's anti-DKK1 antibody is nearing a data readout in gastric/GEJ cancer. $BGNE $XBI https://seekingalpha.com/article/4692763-leap-therapeutics-the-distinguish-trial-provides-a-near-term-catalyst

Pika_Capital Posted - 1 week ago

$bgne monster quarter. This should be $400 stock

DonCorleone77 Posted - 1 week ago

$BGNE BeiGene reports Q1 EPS ($2.41), consensus ($2.54) Reports Q1 revenue $752M, consensus $676.45M. "We are pleased to present another quarter of strong financial results. Supported by our tremendous global growth in revenue, we have now ascended into the top 15 of global oncology innovators based on total oncology sales. We also continue to make significant improvement in our operating leverage as we progress to sustainable profitability," said John Oyler, CEO. "We strengthened our hematology leadership with BRUKINSA, now the BTK inhibitor with the broadest label in the class, as we advance our innovative pipeline of therapies for hematologic malignancies. With TEVIMBRA now approved for use in the U.S. and Europe, we look forward to rapidly advancing our deep pipeline of solid tumor therapies to match our leadership in hematology and continue to solidify our reputation as a global oncology innovator."

epsguid Posted - 1 week ago

$BGNE reported a loss of $2.41, consensus was ($2.98) via @eWhispers #epsbeat http://eps.sh/d/bgne

Stock_Titan Posted - 1 week ago

$BGNE BeiGene Reports First Quarter 2024 Financial Results and Business Updates https://www.stocktitan.net/news/BGNE/bei-gene-reports-first-quarter-2024-financial-results-and-business-8nbh147x2uz7.html

Aigner_Andreas Posted - 2 weeks ago

TD SELL $BGNE at 162.25, Supp 129.52 Resis 162.25 R25 HiLo 26% T1Y 267 buy 1.9 DIV N/A #BeiGene Lt #stocks #trading #finance #market

Pika_Capital Posted - 2 weeks ago

$bgne beautiful recovery. Chartists, what do you see here

MaverikIT Posted - 04/25/24

@net0trader @Cash4freedom @CycleTrade @IsabellaDC @DonCorleone77 @RonIsWrong @Wigglyick @Im_not_Mr_Lebowski $PI - wowsa ! $KEX $VRT $ALAR $BGNE ....

MaverikIT Posted - 04/25/24

@RonIsWrong @DonCorleone77 @net0trader @Wigglyick @Cash4freedom @Im_not_Mr_Lebowski @IsabellaDC @CycleTrade $BGNE $FUTU $CWEB $PDD

wgreystone Posted - 04/25/24

$IBRX NSCLC is one of the hardest cancer types to treat. Hence, $BGNE 's new drug only saw a few weeks OS improvement compared to SOC and still got approved recently. Doubling OS in this indication is just unheard of, AFAIK..

Stock_Titan Posted - 04/24/24

$BGNE Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting https://www.stocktitan.net/news/BGNE/global-oncology-innovator-bei-gene-highlights-new-data-across-6a0204ka3sm9.html

G_Trade Posted - 04/24/24

$SLS $BGNE Remember ✅💎 https://www.prnewswire.com/news-releases/genfleet-and-beigene-enter-into-trial-collaboration-for-a-potentially-first-in-class-combination-therapy-to-initiate-phase-ibii-study-of-gfh009-cdk9-inhibitor-and-brukinsa-zanubrutinib-treating-diffuse-large-b-cell-lymphoma-302101904.html

G_Trade Posted - 04/24/24

$SLS $BGNE Remember: After r/r AML and PTCL, we are now going after DLBCL - very proud of our development partner GenFleet Therapeutics for dosing the first patient in this Ph 1b/2 study, under a clinical trial and collaboration agreement with BeiGene combining GFH009 (SLS009) with Beigene’s BTKi BRUKINSA® (zanubrutinib) - this study is currently run in China only and sponsored by Genfleet. The SLS009-BTKi combination has been previously tested pre-clinically, with exciting data, and hopefully patients will benefit from this innovative approach. Our partnership with Genfleet allows us to tackle various indications cost- and time effectively as Genfleet focuses on the lymphomas and we @Sellas focus on leukemia at this point and pediatric tumor types via the NCI PIVOT program, and potentially solid tumors, with our recent biomarkers identification yielding remarkable (unprecedented) responses in r/r AML. Exciting times ahead…with lots of data expected!

Pika_Capital Posted - 04/23/24

@jgarn $bgne is biotech with GLOBAL footprint but algos throw it in China basket because of it's CN subsidiary and HK listing.

RockyTSTH Posted - 04/23/24

$BGNE BeiGene shares are trading higher after the European Commission approved Tislelizumab for non-small cell lung cancer across three indications, including first- and second-line use.

Pika_Capital Posted - 04/23/24

$BGNE this stock should have never touched $120s but thanks for shares mfkers

DonCorleone77 Posted - 04/23/24

$BGNE BeiGene receives European Commission approval for tislelizumab BeiGene announced that the European Commission has approved tislelizumab as a treatment for non-small cell lung cancer across three indications, including first- and second-line use. "Tislelizumab is foundational for BeiGene's solid tumor portfolio and has demonstrated its potential across multiple tumor types, including NSCLC, in which there remains a significant unmet need at all stages of the disease," said Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeiGene. "Today's EC authorization marks the second in the region for tislelizumab, with both NSCLC and locally advanced or metastatic esophageal squamous cell carcinoma now approved in the European Union. Second-line use in ESCC was also approved just weeks ago by the U.S. Food and Drug Administration, putting us well on our way to fulfilling our commitment to bring this innovative therapy to many more patients around the world."

Stock_Titan Posted - 04/23/24

$BGNE BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer https://www.stocktitan.net/news/BGNE/bei-gene-receives-european-commission-approval-for-tislelizumab-as-cm9cuz0s4t54.html

raj0511 Posted - 1 month ago

$BGNE

insiderbuyingselling Posted - 1 month ago

$BGNE new insider selling: 50000 shares. http://insiderbuyingselling.com/?t=BGNE

DonCorleone77 Posted - 1 month ago

$LLY $VRTX $BGNE $AVBP $DNTH Drugmakers look to alternative suppliers after draft U.S. legislation, FT says Western pharmaceutical companies are looking into alternative suppliers after the release of a draft U.S. legislation that is seeking to restrict a Chinese drug developer and manufacturer over national security concerns, Oliver Barnes, Ian Johnston, and Eleanor Olcott of The Financial Times says. The Biosecure Act would prohibit U.S. companies receiving federal grant money from working with four Chinese biotech companies, including WuXi AppTec and WuXi Biologics. Eli-Lilly (LLY), Vertex Pharmaceuticals (VRTX), and BeiGene (BGNE), among others, have been discussing with rival contract manufacturers to diversify production, several people familiar with discussions said. ArriVent BioPharma (AVBP) and Dianthus Therapeutics (DNTH) are also exploring alternative manufacturing options.

MUNEMAKER Posted - 1 month ago

$BGNE Is the gd paint dry yet? Lol

zhima Posted - 1 month ago

$BGNE

erevnon Posted - 03/27/24

Bernstein maintains BeiGene $BGNE at Market Perform and lowers the price target from $196 to https://marketsblock.com/stock-upgrades-and-downgrades/

TickerDD_com Posted - 03/21/24

From 3/13/2024, looking back across 22 Month-Ends for BGNE, Percentage Change of Average Monthly Price had More Positives (59%) while Percentage Change of Average Monthly Volume had All Positives (100%) $BGNE #BGNE #BGNEStock #TickerDD https://www.youtube.com/watch?v=yQ0_I2NTcW4

SierraNevada Posted - 1 month ago

$BGNE The Top 25 Biotechnology Companies of 2024 | The Healthcare Technology Report. https://thehealthcaretechnologyreport.com/the-top-25-biotechnology-companies-of-2024/

DonCorleone77 Posted - 2 months ago

$BGNE BeiGene receives FDA approval for Tevimbra BeiGene announced that the U.S. Food and Drug Administration has approved TEVIMBRA as monotherapy for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor. TEVIMBRA will be available in the U.S. in the second half of 2024. "Today's FDA approval of TEVIMBRA for patients with ESCC who have previously received chemotherapy, along with its ongoing review of our BLA for first-line ESCC patients, represents a significant step in our commitment to bringing this therapy to more patients around the world," said Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeiGene. "As BeiGene's first drug candidate produced through our immuno-oncology program and second approved medicine in the U.S., TEVIMBRA is poised to be a critical pillar of our solid tumor development program...."

Stock_Titan Posted - 2 months ago

$BGNE BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy https://www.stocktitan.net/news/BGNE/bei-gene-receives-fda-approval-for-tevimbra-r-for-the-treatment-of-kiy5e4jvokih.html